Summarized by Masters of Longevity from Lifespan.io.
A science news piece about a clinical trial that assessed a lung-fibrosis drug’s effects on blood-based aging biomarkers, inviting readers to learn how researchers incorporated multiple proteomic aging clocks into disease-focused research.
Key Takeaways
- A randomized 12-week Phase 2a trial found rentosertib lowered proteomic age estimates most with a 30 mg twice-daily split dose.
- Treatment altered levels of 326 blood proteins, including fibrosis, metabolism, and cellular stress–related proteins.
- Proteins linked to cellular senescence decreased with treatment while they tended to increase in placebo participants.
